Jaguar health and napo pharmaceuticals announce title of abstract regarding patient outcomes associated with cancer therapy-related diarrhea accepted for poster presentation at the american society of clinical oncology 2021 annual meeting

San francisco, ca / accesswire / april 29, 2021 / jaguar health, inc. (nasdaq:jagx) today announced the title of the abstract regarding patient outcomes associated with cancer therapy-related diarrhea ("ctd") by napo pharmaceuticals, inc. ("napo"), jaguar's wholly owned subsidiary, and napo's collaborators that has been accepted for poster presentation at the american society of clinical oncology (asco®) annual meeting, which will be held virtually from june 4-8, 2021. the title of the accepted poster presentation is: the impact of cancer-related diarrhea on changes in cancer therapy patterns: real world evidence poster session: symptoms and survivorship the lead author of the study is pablo c.
JAGX Ratings Summary
JAGX Quant Ranking